Aditya Birla Sun Life Pharma & Healthcare Fund Regular-Growth
The fund is rated 2 stars. The strongest area was balance between returns and downside risk, while investment selection within each industry provided some support. Investment selection within each asset type did not provide enough support for a higher rating. Higher annual fee of 2.29% was a minor drawback.
This fund has a bad track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a good risk-reward ratio. It is important to note, however, that this fund has a 1102.73 AUM and a 2.29 expense ratio. Considering all these factors, we have rated this fund as 2.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 8 Oct 2026
Risk ratios
As of 30 Sep 2026
Portfolio
As of 31 Aug 2026
Market-cap split
Sector allocation
Holdings (40)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd. | 9.57% | ₹105.51 Cr | 2,08,262 |
| Sun Pharmaceutical Industries Ltd. | 9.19% | ₹101.39 Cr | 5,10,815 |
| Apollo Hospitals Enterprise Ltd. | 6.85% | ₹75.58 Cr | 84,936 |
| Cipla Ltd. | 5.16% | ₹56.95 Cr | 4,04,098 |
| Aurobindo Pharma Ltd. | 4.53% | ₹50.01 Cr | 2,91,254 |
| Ajanta Pharma Ltd. | 4.22% | ₹46.58 Cr | 1,29,312 |
| Sai Life Sciences Ltd. | 4.20% | ₹46.31 Cr | 3,17,245 |
| Mankind Pharma Ltd. | 3.41% | ₹37.64 Cr | 1,55,574 |
| Lupin Ltd. | 3.10% | ₹34.19 Cr | 1,56,214 |
| Abbott India Ltd. | 3.03% | ₹33.43 Cr | 12,933 |
Fund details
Long term capital growth. investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
Exit load of 1% if redeemed within 30 days.